Market closed
Cognition Therapeutics/$CGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cognition Therapeutics
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Ticker
$CGTX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
27
Website
CGTX Metrics
BasicAdvanced
$23M
-
-$0.86
1.03
-
Price and volume
Market cap
$23M
Beta
1.03
52-week high
$0.50
52-week low
$0.31
Average daily volume
619K
Financial strength
Current ratio
2.653
Quick ratio
2.486
Long term debt to equity
1.824
Total debt to equity
4.341
Interest coverage (TTM)
-2,158.64%
Management effectiveness
Return on assets (TTM)
-103.15%
Return on equity (TTM)
-157.19%
Valuation
Price to book
1.19
Price to tangible book (TTM)
1.19
Price to free cash flow (TTM)
-0.521
Growth
Earnings per share change (TTM)
-0.00%
3-year earnings per share growth (CAGR)
-34.99%
CGTX News
AllArticlesVideos
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes
GlobeNewsWire·2 weeks ago
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025
GlobeNewsWire·3 weeks ago
Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cognition Therapeutics stock?
Cognition Therapeutics (CGTX) has a market cap of $23M as of April 17, 2025.
What is the P/E ratio for Cognition Therapeutics stock?
The price to earnings (P/E) ratio for Cognition Therapeutics (CGTX) stock is 0 as of April 17, 2025.
Does Cognition Therapeutics stock pay dividends?
No, Cognition Therapeutics (CGTX) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Cognition Therapeutics dividend payment date?
Cognition Therapeutics (CGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cognition Therapeutics?
Cognition Therapeutics (CGTX) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.